Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 5.2%

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 2,210,000 shares, an increase of 5.2% from the December 15th total of 2,100,000 shares. Currently, 2.6% of the shares of the company are short sold. Based on an average daily volume of 875,000 shares, the short-interest ratio is presently 2.5 days.

Analysts Set New Price Targets

CMPX has been the subject of a number of analyst reports. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Finally, D. Boral Capital restated a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Stock Up 4.0 %

NASDAQ CMPX traded up $0.10 on Friday, hitting $2.60. 1,402,133 shares of the company’s stock were exchanged, compared to its average volume of 1,506,824. Compass Therapeutics has a 52 week low of $0.76 and a 52 week high of $2.70. The stock has a 50-day moving average of $1.62 and a 200-day moving average of $1.50.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Equities analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds have recently made changes to their positions in CMPX. Geode Capital Management LLC increased its position in Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after buying an additional 356,352 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after acquiring an additional 31,433 shares during the last quarter. Barclays PLC boosted its holdings in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after acquiring an additional 70,200 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.